A. Sandler

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

Benjamin Besse, Melissa Johnson, P.A. Jänne et al. · European Journal of Cancer · 2015 · 72 citations

Medicine, Oncology, Pharmacology +16

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Fabrice Barlési, K. Park, Fortunato Ciardiello et al. · Annals of Oncology · 2016 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

Solange Peters, A.W. Kim, Benjamin Solomon et al. · Annals of Oncology · 2019 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Federico Cappuzzo, Michael McCleod, Maen Hussein et al. · Annals of Oncology · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacology +12

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

Marcin Kowanetz, Wei Zou, David S. Shames et al. · Annals of Oncology · 2016 · 48 citations · Full text

Medicine, Oncology, Pharmacology +16